Beruflich Dokumente
Kultur Dokumente
1. How did you choose your proposed course and institution? (perbaiki yg ini ya, Ayu)
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis bacteria
attacking organs particularly lung. According to WHO data, 1.5 million people suffering from TB
died in 2014. Indonesia is one of the countries contributing to death number of TB in the world.
Indonesia has performed TB restraint for a long duration. Although in 2012 TB prevalence
lowered, in 2015 TB prevalence has increased and reached 647 cases per 100,000 residents and
resulted in the raising of Indonesia’s rank as the third country with the highest case of TB in the
world.
One of factors affecting this high prevalence is patient’s low adherence because of
numeral and long term medication. TB drug administration by oral route also results in low drug
bioavailability so that only small amount of drug can reach the target, alveolus. Moreover, the
drugs passing systemic blood system cause some adverse effects.
To overcome the problems, developing inhalable nanoparticles can help increase patient
adherence, prevent the raise of drug resistance and adverse effect. Pharmacy nanoparticles in
Indonesia has been preferred by many scientists. But lack in instruments to perform
characterization of nanoparticles is still a dilemma to advance the field, for instance unavailability
of Dynamic Light Scattering. Moreover, pulmonary drug delivery of nanoparticles has not been
improved yet and based on observation, research publication of nanoparticles pulmonary drug
delivery formulation is not available in Indonesia. Because of instruments and human resource
boundaries and also urgency to develop the formulation for TB case, this field has potency to be
developed in advance stage.
From my observation of institution in Australia, Monash University offers Master by
Research of Pharmaceutical Science by preparing research program topic of Drug Powder
Inhalation Product for anti-infective. I am sure this proposed study can provide knowledge to solve
the TB problem and develop drug delivery.
4. Please :
a) Give up to three practical examples of how you intend to use the knowledge, skills,
and connections you will gain from your scholarship. Possible tasks can be
personal and/ or professional; and
b) List any possible constrains you think may prevent you from achieving this tasks.
Practical examples that I intend to use my knowledge and skill from the scholarship are:
- Further research and development in nanoparticle drug delivery system for TB drugs by
pulmonary route are very important to be performed in order to overcome the raising of TB
case in Indonesia. Submitting research proposal to the government or institution that provides
research fund for researchers in Indonesia is one of the plans that I would like to perform to
improve the research about nanoparticle formulation of TB drugs which is administered by
pulmonary, and also other topics related to pulmonary drug delivery system. The researches
will be performed by utilizing available resources and facilities in Indonesia because of limited
fund, materials, and facilities prepared by government to perform the research.
- Besides performing some mini researches that I have mentioned above, the next plan I intend
to do is being a lecture in the university where I completed my bachelor education. By
becoming lecture is one of the ways to apply my knowledge that I have gained from my study
to the students and also it is expected to be able to further the students’ knowledge and
awareness of advanced pharmaceutical science. Moreover, by using that I am able to
accustom and embrace the continuity of knowledge and science in pulmonary drug delivery
system not only by delivering the theory but also by applying in researches performed by
students or even other scientists in the pharmacy field.
However, there are some constraints which are probable to come out in order to bring on
my plans that I have revealed above, those which are less supported by government and/ or
institution to undergo the research. Limited fund can be the constraint for that reason, because
government still grants small amount of fund in the field of scientific research. Another problem is
incomplete and insufficient instruments as well as facilities, as a consequence the research will
be performed by benefit material and facilities which are available in Indonesia and there is
probability to omit some parameters and characterizations in the research.
Research Plan
Research Title:
Characterization and Evaluation of Inhalable Dry Powder Formulation of Liposomal Anti-
tubercular Drug
Objectives:
This research is aimed at formulating, determining characteristics, and evaluating preclinical study
of anti-tubercular drug which is prepared into inhalable dry powder liposome so that this
formulation is expected to act in targeted tissue of the lung infected by Mycobacterium
tuberculosis, increase patient adherence and reduce the adverse effects of anti-tubercular drug
as well.
References:
1. Garg T., Rath G., Goyal A. K. Inhalable chitosan nanoparticles as antitubercular drug carriers
for an effective treatment of tuberculosis. Artificial Cells, Nanomedicine, and Biotechnology:
1-5 (2015).
2. Bhavya M. V., Gowda D. V., Srivastava A., Aravind Ram A. S., Osmani R. A. M. Development
and Characterization of Ethionamide loaded microparticles as Dry Powder Inhalers for Multi-
drug Resistant Tuberculosis. Der Pharmacia Lettre 8 (8): 273-279 (2016).
3. Podda G. Chitosan and PLGA Microspheres as Drug Delivery System Against Pulmonary
Mycobacteria Infections (Dissertation). University of Cagliari Department Farmaco Chimico
Tecnologico.
4. Parumasivam T., Chang R. Y. K., Abdelghany S., Ye T. T., Britton W. J., Chan H. Dry powder
inhalable formulations for anti-tubercular therapy. Advanced Drug Delivery Reviews xxx: xxx–
xxx (2016).
5. M. Rajan, V. Raj. Formation and characterization of chitosan-polylacticacid-polyethylene
glycol-gelatin nanoparticles: A novel biosystem for controlled drug delivery. Carbohydrate
Polymers 98: 951– 958 (2013).
6. Ong H. X., Traini D., Young P. M. Pharmaceutical applications of the Calu-3 lung epithelia
cell line. Expert Opin. Drug Deliv. 10 (9): 1287-1302 (2013).
7. Paranjpe M., Müller-Goymann C. C. Nanoparticle-Mediated Pulmonary Drug Delivery: A
Review. Int. J. Mol. Sci. 15: 5852-5873 (2014)